Proteomic profiles of cytokines and chemokines in moderate to severe depression: Implications for comorbidities and biomarker discovery
- PMID: 38435722
- PMCID: PMC10906146
- DOI: 10.1016/j.bbih.2024.100731
Proteomic profiles of cytokines and chemokines in moderate to severe depression: Implications for comorbidities and biomarker discovery
Abstract
Objective: This study assessed the proteomic profiles of cytokines and chemokines in individuals with moderate to severe depression, with or without comorbid medical disorders, compared to healthy controls. Two proteomic multiplex platforms were employed for this purpose.
Metods: An immunofluorescent multiplex platform and an aptamer-based method were used to evaluate 32 protein analytes from 153 individuals with moderate to severe major depressive disorder (MDD) and healthy controls (HCs). The study focused on determining the level of agreement between the two platforms and evaluating the ability of individual analytes and principal components (PCs) to differentiate between the MDD and HC groups. Additionally, the study investigated the relationship between PCs consisting of chemokines and cytokines and comorbid inflammatory and cardiometabolic diseases.
Findings: Analysis revealed a small or moderate correlation between 47% of the analytes measured by the two platforms. Two proteomic profiles were identified that differentiated individuals with moderate to severe MDD from HCs. High eotaxin, age, BMI, IP-10, or IL-10 characterized profile 1. This profile was associated with several cardiometabolic risk factors, including hypertension, hyperlipidemia, and type 2 diabetes. Profile 2 is characterized by higher age, BMI, interleukins, and a strong negative loading for eotaxin. This profile was associated with inflammation but not cardiometabolic risk factors.
Conclusion: This study provides further evidence that proteomic profiles can be used to identify potential biomarkers and pathways associated with MDD and comorbidities. Our findings suggest that MDD is associated with distinct profiles of proteins that are also associated with cardiometabolic risk factors, inflammation, and obesity. In particular, the chemokines eotaxin and IP-10 appear to play a role in the relationship between MDD and cardiometabolic risk factors. These findings suggest that a focus on the interplay between MDD and comorbidities may be useful in identifying potential targets for intervention and improving overall health outcomes.
Keywords: Biomarkers; Chemokines; Cytokines; Inflammation; Major depressive disorder; Proteomics.
© 2024 The Authors.
Conflict of interest statement
There is no conflict of interest among all the authors with either Luminex or Somalogic.BL and IK are a full-time employees of the biopharmaceutical company Alkahest, Inc.
Figures


Similar articles
-
Serum CC Chemokines as Potential Biomarkers for the Diagnosis of Major Depressive Disorder.Psychol Res Behav Manag. 2022 Oct 11;15:2971-2978. doi: 10.2147/PRBM.S384267. eCollection 2022. Psychol Res Behav Manag. 2022. PMID: 36310625 Free PMC article.
-
Reduced CXCL1/GRO chemokine plasma levels are a possible biomarker of elderly depression.J Affect Disord. 2019 Apr 15;249:410-417. doi: 10.1016/j.jad.2019.02.042. Epub 2019 Feb 13. J Affect Disord. 2019. PMID: 30826620
-
Evaluation of serum interleukin-12 and interleukin-4 as potential biomarkers for the diagnosis of major depressive disorder.Sci Rep. 2024 Jan 18;14(1):1652. doi: 10.1038/s41598-024-51932-9. Sci Rep. 2024. PMID: 38238514 Free PMC article.
-
Peripheral cytokine and chemokine alterations in depression: a meta-analysis of 82 studies.Acta Psychiatr Scand. 2017 May;135(5):373-387. doi: 10.1111/acps.12698. Epub 2017 Jan 25. Acta Psychiatr Scand. 2017. PMID: 28122130
-
A review of the relationship between proinflammatory cytokines and major depressive disorder.J Affect Disord. 2014 Dec;169:15-20. doi: 10.1016/j.jad.2014.07.032. Epub 2014 Jul 30. J Affect Disord. 2014. PMID: 25128861 Review.
References
-
- American Psychiatric Association . fifth ed. 2013. Diagnostic and Statistical Manual of Mental Disorders.
-
- Brietzke E., Kauer-Sant'Anna M., Teixeira A.L., Kapczinski F. Abnormalities in serum chemokine levels in euthymic patients with bipolar disorder. Brain Behav. Immun. 2009;23:1079–1082. - PubMed
LinkOut - more resources
Full Text Sources